Biotricity is Leading the Future of Cardiac Health Care with Innovative Remote Monitoring Solutions

Biotricity is revolutionizing cardiac care with cutting-edge remote monitoring solutions, providing real-time insights for better health management and prevention. End Quote

(1888PressRelease) January 23, 2025 - REDWOOD CITY, California - Biotricity Inc. (OTCQB:BTCY), Biotricity, Stands out as a leader among heart monitoring companies and is revolutionizing the cardiac care industry with it cutting-edge remote monitoring solutions. The company’s premier product, Biocore, is the only connected 3-lead patch monitor in the world. Biocore enables healthcare providers to continuously monitor patients in the remote setting for longer durations of time compared with traditional diagnostic methods, ensuring more proactive and better patient care.

Heart disease is difficult to diagnose because symptoms can be intermittent and individuals can be asymptomatic, especially in early stages. The need for early continuous, accurate heart health monitoring has never been more critical. Traditional heart diagnostic methods, like in-office ECGs, can miss abnormalities due to the short testing period. This leaves patients vulnerable to potentially missed conditions. Heart monitor patches, like Biocore, provides 24/7 monitoring of heart activity. This continuous flow of data enables healthcare providers to detect and address potential heart issues before they become life-threatening.

Designed for ease of use, Biocore integrates seamlessly into patients’ daily lives. Patients can wear Biotricity’s heart monitor patches throughout their normal routine, ensuring that their heart health is constantly being tracked. The device securely transmits heart data continuously to healthcare providers, allowing for analysis and proactive decision-making. This constant connection between patients and doctors ensures early detection of abnormal rhythms and other heart conditions, ultimately improving health outcomes. Biotricity is also reducing healthcare costs by offering remote monitoring solutions that minimize the need for frequent in-person visits. Patients with chronic conditions like arrhythmia or heart failure can monitor their heart health from the comfort of their homes. This reduces the strain on the healthcare industry by lowering costs for patients and the system, and decreasing reliance on emergency interventions.

Biotricity is a forward-thinking company and can integrate its heart monitoring technology with electronic health record (EHR) systems. This integration allows heart monitoring companies and healthcare providers to have a more comprehensive and accurate view of a patient’s health. By improving collaboration and communication among care teams, the solution enables more personalized treatment plans and better patient care.

The future of cardiac care is undeniably shifting towards remote monitoring, and Biotricity is at the forefront of this movement. With remote monitoring solutions like Biocore, the company is helping patients take control of their heart health while providing healthcare professionals with the tools they need to improve care. Biotricity continues to innovate and develop technologies that make heart health monitoring more accessible, efficient, and accurate.

For more information about Biotricity and its innovative remote monitoring solutions, visit https://biotricity.com/.

About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contacts:
Investor relations:
Biotricity Investor Relations
Investors ( @ ) biotricity dot com

###

space

Other Related Press Releases